Precision Business Insights
Portfolio

 

Research Reports

Non-Dystrophic Myotonia Disorder Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025 (Copy)

Global Non-Dystrophic Myotonia Disorder Treatment Market: By Drug Class (Anti-arrhythmic Class IB Drugs, Carbonic Anhydrase Inhibitors, Third-line Antimyotonic Agents, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

Global Non-Dystrophic Myotonia Disorder Treatment Market Report Description:

Global non-dystrophic myotonia disorder treatment market report gives comprehensive outlook on non-dystrophic myotonia disorder treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global non-dystrophic myotonia disorder treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, route of administration, distribution channel, and region. This report studies global non-dystrophic myotonia disorder treatment market dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global non-dystrophic myotonia disorder treatment market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global non-dystrophic myotonia disorder treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global non-dystrophic myotonia disorder treatment market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global non-dystrophic myotonia disorder treatment products.

 

Global Non-Dystrophic Myotonia Disorder Treatment Market:

The global Non-Dystrophic Myotonia Disorder Treatment market estimated to be valued US$ XX Mn in 2018 and poised to grow at significant CAGR over 2019-2025 due to increase in prevalence of non-dystrophic myotonia disorder around the globe. Moreover, rise in R&D for the development of newer therapeutics is expected to propel the non-dystrophic myotonia disorder treatment market over the forecast years.

 

Increase in the R&D for the Development of Newer Therapeutics

Increase in R&D activities for the development of newer therapeutics for the non-dystrophic myotonia disorder treatment is a key factor drive the market over the forecast years. Moreover, rise in awareness about the non-dystrophic myotonia among the healthcare professionals in developed and developing countries, favorable reimbursement policies, and increase in healthcare expenditure are anticipated to propel the non-dystrophic myotonia disorder treatment market over the forecast timeframe.

 

North America Accounts for Larger Market Revenue Share in Global Non-Dystrophic Myotonia Disorder Treatment Market

North America accounted for larger revenue share in global non-dystrophic myotonia disorder treatment market with significant CAGR owing to higher disease treatment seeking rate coupled with rise in prevalence of non-dystrophic myotonia disorder treatment are anticipated to propel the market in North America region. Europe non-dystrophic myotonia disorder treatment market projected to grow at significant rate owing to increase in research and development on newer therapeutics and favorable reimbursement policies are expected to enhance the market over the forecast years.

 

Competition Assessment

Key player’s profiles in the global non-dystrophic myotonia disorder treatment market include:

  • Novartis AG (Switzerland)
  • Johnson and Johnson Services, Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Allergan plc (U.K.)
  • Sanofi S.A. (France)
  • Lupin Ltd. (India)
  • Pfizer, Inc. (U.S.)

 

Global non-dystrophic myotonia disorder treatment market is surging owing to approval and launch of newer therapeutics by the market players. For instance, In October 2018, Lupin received the European Medical Agency recommended granting a marketing authorisation for Namuscla (mexiletine hydrochloride) for the treatment of adult patients with non-dystrophic myotonia.

 

Key Findings of the Report:

 

  • Global non-dystrophic myotonia disorder treatment market expanding at significant CAGR over 2019 to 2025 owing to increase in the prevalence of non-dystrophic myotonia disorder.
  • Based on drug class, anti-arrhythmic class IB drugs accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global non-dystrophic myotonia disorder treatment market

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

Detailed Segmentation

 

By Drug Class

  • Anti-arrhythmic Class IB Drugs
  • Carbonic Anhydrase Inhibitors
  • Third-line Antimyotonic Agents
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Geography

 

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Table of Content

  1. Executive Summary
  2. Global Non-Dystrophic Myotonia Disorder Treatment Market Introduction
    • Global Non-Dystrophic Myotonia Disorder Treatment Market – Taxonomy
    • Global Non-Dystrophic Myotonia Disorder Treatment Market –Definitions
      • Drug Class
      • Route of Administration
  1. Global Non-Dystrophic Myotonia Disorder Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Non-Dystrophic Myotonia Disorder Treatment Market Dynamic Factors – Impact Analysis
    • Global Non-Dystrophic Myotonia Disorder Treatment Market – Competition Landscape
    • Epidemiology
  2. Global Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025
    • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global Non-Dystrophic Myotonia Disorder Treatment Market, By Drug Class, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • Anti-arrhythmic Class IB Drugs
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Carbonic Anhydrase Inhibitors
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Third-line Antimyotonic Agents
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
        • Market Opportunity Analysis
  1. Global Non-Dystrophic Myotonia Disorder Treatment Market Forecast, By Route of Administration, 2014 – 2018 and Forecast, 2019 – 2025
    • Oral
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Non-Dystrophic Myotonia Disorder Treatment Market Forecast, By Distribution Channel, 2014 – 2018 and Forecast, 2019 – 2025
    • Hospital Pharmacies
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Non-Dystrophic Myotonia Disorder Treatment Market Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Region, 2019 – 2025
  2. North America Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • By Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Arrhythmic Class IB Drugs
      • Carbonic Anhydrase Inhibitors
      • Third-line Antimyotonic Agents
      • Others
    • Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Country, 2019 – 2025
    • North America Non-Dystrophic Myotonia Disorder Treatment Market Dynamics – Trends
  3. Europe Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • By Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Arrhythmic Class IB Drugs
      • Carbonic Anhydrase Inhibitors
      • Third-line Antimyotonic Agents
      • Others
    • Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Country, 2019 – 2025
    • Europe Non-Dystrophic Myotonia Disorder Treatment Market Dynamics – Trends
  4. Asia-Pacific Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • By Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Arrhythmic Class IB Drugs
      • Carbonic Anhydrase Inhibitors
      • Third-line Antimyotonic Agents
      • Others
    • Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Country, 2019 – 2025
    • Asia-Pacific Non-Dystrophic Myotonia Disorder Treatment Market Dynamics – Trends
  5. Latin America Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • By Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Arrhythmic Class IB Drugs
      • Carbonic Anhydrase Inhibitors
      • Third-line Antimyotonic Agents
      • Others
    • Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Country, 2019 – 2025
    • Latin America Non-Dystrophic Myotonia Disorder Treatment Market Dynamics – Trends
  6. Middle East and Africa Non-Dystrophic Myotonia Disorder Treatment Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)
    • By Drug Class Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Anti-Arrhythmic Class IB Drugs
      • Carbonic Anhydrase Inhibitors
      • Third-line Antimyotonic Agents
      • Others
    • Route of Administration Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2014 – 2018 and Forecast 2019 – 2025 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Non-Dystrophic Myotonia Disorder Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel, and Country, 2019 – 2025
    • MEA Non-Dystrophic Myotonia Disorder Treatment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Route of Administration & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis AG (Switzerland)
      • Johnson and Johnson Services, Inc. (U.S.)
      • GlaxoSmithKline plc (U.K.)
      • Allergan plc (U.K.)
      • Sanofi S.A. (France)
      • Lupin Ltd. (India)
      • Pfizer, Inc. (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553